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jects, particularly those with a therapeutic objective, from the distraction, the
time and expense needed to defend civil court actions.
UNITED STATES SPEAKER
Michael J. Wagner t
First, thanks for having me. My firm was involved in the first constitu-
tional challenge to that statute. As you can imagine, it was pretty controver-
sial. In 1983, one of my partners sought to withhold documents from disclo-
sure in litigation for precisely the kind we just heard Bruce talking about,
documents related to classic peer review, analysis of performance of a re-
search trial, analysis of performance of physicians within the context of their
licensure and their work.
The suit involved a very well-financed, influential and creative plaintiffs
lawyer. We have elected judges whose campaigns require replenishment
every ten years or eight years. One of those plaintiffs lawyers brought it to
one of the judges and said this statute is unconstitutional, and we are being
deprived of our due process rights to know what the hospital said about the
performance of this particular group of doctors. To my partner's unpleasant
surprise the judge agreed that it was unconstitutional, prompting us to take it
up for an appeal to the Illinois Supreme Court, where we succeeded in hav-
ing the ruling reversed and the statute was upheld.
24
Why is that important here? Well, if innovation means anything, it means
that the physicians, for example, who are the clinical investigators in research
trials, can innovate in a way that allows them to be critical of not just the
medication under consideration but also of the performance of each other in
the way they administrator it and the way they develop it. So that is classic
peer review and very important for our purposes today. It remains a vital
statute in Illinois, but it is under siege every year.25 You will see some cases,
1 Michael J. Wagner is a in Baker & McKenzie LLP Litigation Practice Group where he
represents multinational companies engaged in litigation alleging breach of contract, product
liability, fraud, misappropriation of trade secrets, breach of fiduciary duty and executive dis-
loyalty, tortious interference with contract and commercial disparagement. Mr. Wagner regu-
larly has primary counsel responsibility for the defense of class actions and multi-district
litigation involving commercial and product liability claims. He frequently defends global
manufacturers as they confront mass tort and other litigation involving products ranging from
prescription medications and vaccines to medical devices to food. He also represents software
developers, project managers and IT consultants in commercial disputes.
24 Jenkins v. Wu, 468 N.E.2d 1162 (I11. Sup. Ct. 1984).
25 See, e.g., Ardisana v. Northwest Community Hosp., Inc., 795 N.E.2d 964 (I11. App. Ct.
1st Dist. 2003) (involving a partially successful challenge to a portion of the Medical Studies
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the Barry case being one, the Chicago trust case that Bruce cited, in which
there are efforts to chip away at that statute.26 But at the end of the day, it still
remains that for peer review deliberations of a committee primarily. 27 It is
not simply as occurred in, I believe, the Barry case, where one physician
wrote a letter to the department chair that was deemed not to fall within the
scope of peer review because there wasn't already a convened peer review
deliberation. z8
So that gives you an idea of the creativity of plaintiffs' lawyers using their
enterprising skills to make this less effective. So as a Chicago based trial
lawyer and litigator who regularly represents pharmaceutical companies and
manufacturers of other products, we are delighted to have the statute when it
is available to be applied, but unfortunately, it is pretty narrow in its applica-
tion for most product liability.
With that in mind, I would like to segue over to product liability in par-
ticular and to provide a non-economist's view of the impact of liability on
innovation. There are plenty of specialists in this area, and I can refer you to
those who have written very eloquently on the economic impact, but I want
to provide a U.S. litigator's perspective based on the impact it has had on my
clients and on perhaps clients of yours over the past 25 years since I have
been doing this.
First, it is important to keep in mind the mentality that manufacturers
must have. For anybody who misses the fire side cartoons as I did, I had to
bring this one back. Every manufacturer I know has felt, at some point, like
poor Hal in this cartoon. This falls into the category of only in America. This
is a slide that I pulled off of the internet a couple of years ago. Notice the title
there is "Big Class Action." Now, no plaintiffs lawyer worth his salt will
ever have a web site called "Small Class Action." You have got to have a big
class action. Like the term complex litigator, who wants to be called a simple
litigator, but I digress. Have your case evaluated by a lawyer. When I showed
this to my partners in other jurisdictions - and we have partners who meet in
our disputes practice a couple times a year - they just shake their head in
dismay that where else but America could you have legalized solicitation?
These aren't products out on the fringe. We are talking about batteries for
iPods. They are not limiting themselves to products actions. They have got
labor actions in there, welding rods. Of course, there are a number of phar-
maceuticals in there since they are the easy target and deep pocket.
So let's take a look at the problem. Then we will analyze a few facts and
figures.
Act).
26 Berry v. West Suburban Hosp. Med. Ctr., 788 N.E.2d 75 (I11. App. Ct. 1" Dist. 2003).
27 Chicago Trust Co. v. Cook County Hosp., 698 N.E.2d 641 (Ill. App. Ct. 1st Dist. 1998).
28 Berry, 788 N.E.2d at 77.
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While I am not an economist, I can read the numbers and see the impact it
is having on my clients and want to share those with you. As I focus, for a
few minutes, on what ought to be the proper product liability, I will offer a
few editorial comments, and invite yours, while discussing the mismatch that
I see and have seen for 25 years between where the law is and where the
facts are with the objectives of what ought to be and where the reality is for
our clients. I then want to suggest two or three very simple humble areas for
reform that I think are workable but not yet in place in the states.
Well, let's take a look at the view - a look at the problem from the view of
the industry folks. We are just three hours away from Detroit, so I thought it
appropriate to draw upon an auto industry voice here for Mr. LaSorda, who
speaks from many years of experience and paying many millions of dollars
in legal fees. I want to talk a little bit later about self-critical evaluation and
what it could be in this country, and what it is not, and why this type of an
observation, I think, is really reflective of a critical need to be able to criti-
cize within the scope of manufacturing processes if we are going to have true
innovation.
There was a survey done of Oklahoma business leaders recently that re-
flected a surprisingly high number, higher than I even expected of respon-
dents who said that they had already decided against developing new prod-
ucts or services in order to avoid liability lawsuits.29 Now, it is a smaller
state, a smaller group, not the biggest state in the U.S, but it gives you a fla-
vor for how real this is, and Oklahoma is not perceived as being an un-
friendly business state, unlike Alabama and a few others.3°
I do quite a bit of work with pharmaceutical companies and food compa-
nies, and so this particular perspective struck me. FDA also never weighs in
on liability issues. If you are involved in litigation and wonder why FDA
doesn't stand behind products, it is already approved. They never do that.3
There is a regulation on point.32 You can't get any FDA advisory committee
member to step forward, and you understand why; they don't want to have
these people who have devoted their lives to important research end up
29 THE STATE CHAMBER, SURVEY: LEGAL CLIMATE HURTING JOB GROWTH (2006), available
at http://www.okstatechamber.com/file_upload/SurveyPressRelease21606.pdf (last visited
Nov. 4, 2006).
30 See YING HUANG, ROBERT E. MCCORMICK & LAWRENCE J. MCQUILLAN, PACIFIC
RESEARCH INSTITUTE, ECONOMIC FREEDOM INDEX: 2004 (2004), http://www.pacificresearch.
orglpublsab/entrep/2004/econfreedom/index.html (last visited Nov. 4, 2006) (ranking Okla-
homa as the nineteenth best state for business freedom).
31 See Daniel Troy, FDA Involvement in Product Liability Lawsuits, UPDATE, Jan./Feb.
2003 (discussing the FDA's usual role in product liability cases).
32 TOWERS PERRIN, TILLINGHAST, U.S. TORT COSTS AND CROSS-BORDER PERSPECTIVES:
2005 UPDATE (2005), available at http://www.towersperrin.com/tp/getwebcachedoc?webc=
TILL/USA/2006/200603/2005_Tort.pdf (last visited Nov. 4, 2006).
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spending all their time in product liability cases. At the same time, I wish
there were more public statements taking the form of this one that we could
actually put to use in litigation.
Some facts and figures: Tower, Perrin, Tillinghast has given out very re-
cently a report on the cost of the U.S. tort system; this is box car numbers,
big numbers, but $260 billion dollars is the cost of this system. Obviously,
that's nearly 886 per person, quite high, and this to me is the one that my
partners will say I thought it was bad in the states. I didn't know it was this
bad; that there is a higher percentage of the GDP dedicated to this particular
system of justice than that in any other developed country.33 And it is not
exactly on the downside.
Empirical evidence, both personal and otherwise - I represented a number
of companies, and if you all have here, I would welcome your input on this
one way or the other - but as recently as last month a client of mine ended up
taking a plant that had employed 575 people, and now it is down to 70 peo-
ple, solely because of a single spate of around 15 to 20 lawsuits that have
made it much more difficult for them to produce the product they used to
produce. It is not high tech. It is a food product that happens to be associated
with some food born illness in a particular Government study that was not
well financed, and we think it was misguided, but that created a lot of pres-
sure on the company to make some important decisions. The market pres-
sure, coupled with the publicity, ended up in a very sad state of employment
for that community. My own personal experience also indicates that there is
now a great reluctance to engage in, let alone to document, any in-depth self-
critical analysis among major manufacturers, unless they do it strictly in the
context of an attorney-client privilege. And why is that? Because they don't
want to be hoisted by their own petard, just like Mr. LaSorda said from
Daimler Chrysler.
The availability of insurance, it goes without saying that asbestos has be-
come the poster child for this issue; good luck finding any insurer that will
go near asbestos-containing products. We have one client who is simply a
common carrier, a transporter of asbestos and had no role in the actual sale or
distribution of the product, and yet, it is named in about 400 lawsuits. The
premiums, of course, are sky rocketing where it can be obtained.
How many of you folks remember here in the states and in Canada this
was an issue, the pertussis vaccine crisis of the mid 1980s, the DPT vac-
cine.34 Well, in 1984, there was a program 20/20 aired, and in that program
33 Id.
34 See IMMUNIZATION SAFETY REVIEW COMMrTEE, IMMUNIZATION SAFETY REVIEW:
THIMEROSAL - CONTAINING VACCINES AND NEURODEVELOPMENTAL DisoRDERs 21 (2001)
(discussing media coverage, including 20/20, covering neurological disorders in children who
took the DPT vaccine).
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there were some very sympathetic families like the one that Bruce just de-
scribed. 35 These families had children who had been inoculated with pertus-
sis or whooping cough vaccine, and within a matter of 72 hours or perhaps as
much as a week several of these kids developed intractable seizures, and in a
couple of cases encephalopathy or brain damage and were quite tragically
and permanently brain injured. 36 Because of the temporal association be-
tween the inoculation with this vaccine and the onset of this permanent and
catastrophic illness disease state, there was a great deal of sympathy and an
outcry of publicity after the 20/20 program aired. Within a matter of months,
there were hundreds of lawsuits filed.37 At the time, there were quite a few
manufacturers of the vaccine.38 Why is the vaccine important? Because as
recently as 100 years ago pertussis took the lives of one in three children in
the underdeveloped countries of this world. 39 Afterwards, after the introduc-
tion of the vaccine, of course, it dropped dramatically.40 So it is a real risk,
and those states, after this program aired, began to scale back their support
for pertussis vaccine, Idaho being one.41 There was an outbreak.42 In Mary-
land, there was actually a mini-outbreak there, so there clearly was a need for
this vaccine.43 But the liability problems became really quite daunting." The
client I represented in dozens and dozens of those cases ended up being the
only one of the manufacturers left to be standing; everyone else pulled out.
45
35 Id.
36 id.
37 Id.
38 Vaccination Litigation: After Almost Killing the Childhood Vaccine Market, Trial Law-
yers, Inc. Takes Another Stab at These Vital Medications, TRIAL LAWYERS, INC. HEALTH
CARE: CONDITION CRITICAL: THE LAWSUIT INDUSTRY'S EFFECT ON AMERICAN HEALTH 2005, 10
(2005), http://www.triallawyersinc.com/TLI-HealthCare.pdf.
39 See Whooping Cough, the DPT Vaccine, and Reducing Vaccine Reactions, National
Vaccine Information Center, http://www.909shot.com/Diseases/whooping.htm (last visited
Nov. 4, 2006) (stating that whooping cough is still a problem in the developing countries,
much like it was at the beginning of the 20th century throughout the entire world).
40 John Clemens & Luis Jodar, Introducing New Vaccines into Countries: Obstacles, Op-
portunities, and Complexities, 11 NATURE MEDICINE SUPPLEMENT 4, S12 (2005),
http://www.nature.com/nm/joumal/v 1/n4s/pdf/nml225.pdf.
1 See Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Casual-
ity, The National Academies Press, 2 (1994), http://fermat.nap.edu/books/0309048958/
htnl/2.html (last visited Nov. 4, 2006) (noting that childhood immunization programs were
being faced with economic pressures following increased concern over the side effects of the
pertussis vaccine in the early 1980s).
42 Pertussis Testing in Idaho, 8 IDAHO DISEASE BULLETIN 4, 2 (2002),
http://www.healthandwelfare.idaho.gov/ -Rainbow/Documents/health/2002%2ODecember.pdf.
3 Pertussis Outbreaks - Massachusetts and Maryland, 1992, 42 MORBIDITY AND
MORTALITY WEEKLY REPORT 11, 197 (1993), http://0-www.cdc.gov.millI.sjlibrary.org/mmwr/
PDF/wk/mm4211 .pdf.
44 TRIAL LAWYERS, INC. HEALTH CARE, supra note 16.
45 Id.
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This alarmed, of course, the public health officials of the United States and
Canada, and immediately, they began to look at other alternatives.46 This
resulted in Congress stepping in saying we are going to have not a no fault
system but close to a no fault system in which people can bring an action
under the National Childhood Vaccine Injury Compensation Act.47 What
would fund it? All of us would by the price we pay for the vaccine, which, of
course, tripled in a matter of months.48 That regimen is sort of like a black
lung disease in the coal industry where if certain criteria are met, onset of
encephalopathy within 72 hours without any other obvious cause, then there
will be certain payments made, but the lawsuits remained for some years.49
The footnote to all of this was that, lo and behold, the study done over in
Britain triggered all of this concern from a scientific standpoint. 50 Eventually,
they went back and took a closer look at the epidemiology and it turned out
the right of association between brain damage, onset of encephalopathy and
the vaccine was nowhere near as great as first thought.5' So tragically, quite a
bit of production of the vaccine had been curtailed, but in the meantime, re-
search showed there was really no reason to have the concern in the first
place. Some plaintiffs' lawyers would disagree with me on that, but I think
the science has shown that the manufacturers were better supported.
Who has not heard about the diet drug or Fen-phen litigation?52 We all
know about this. One of our clients, Wyeth, the man in charge of that, Bill
Rowain, I asked him for his input before, of course, putting his client's name
up on the screen, and he points out one interesting fact that the reserves for
damages are $20 billion dollars or $21 billion dollars actually right now in
2006. 53 In an e-mail that he sent me, he pointed out imagine the better uses to
which we could have put the $15.4 billion dollars we have already spent; this
46 Id.
47 Id.
48 Paul Offit, Vaccine History Shows Need to Update VICP Law, THE HiLL NEWS (2005),
http://www.hillnews.com/thehill/export/TheHill/News/Frontpage/l11505/offit.html (last vis-
ited Nov. 4, 2006).
49 Wendy K. Mariner, Update L Legislative Report: The National Vaccine Injury Compen-
sation Report, HEALTh AFFAIRS, 255 (1992), http://content.healthaffairs.org/cgi/re-
print/I1 /l/255.pdf.
50 Margaret Ann Goetz, Pertussis Vaccination and Serious Central Nervous System Disor-
ders: Early Case Series Evidence and Public Reaction, DRUGS AND DEVICES INFORMATION
LINE, (1997), http://www.hsph.harvard.edu/Organizations/DDl/pertuss.html (last visited
Nov. 4, 2006).
51 Offit, supra note 26.
52 Advancing the Rights of Patients, Fen Phen Legal Resources.Com: A Newsletter from
the National Law Firm of Lieff, Cabraser, Heimann, and Bernstein, LLP (2006),
http://www.fen-phen-legal-resources.com (last visited Nov. 3, 2006).
3 Appeals Court Does Rare Reversal in Diet-Drug Case, PRIMARY PULMONARY
HYPERTENSION NEWS (2006), http://pph-net.org/news/pph-news-0133.htm (last visited, Nov.
3, 2006).
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$21 billion dollars is just reserved, but they have actually spent on this litiga-
tion $15.3 billion dollars. Obviously, as he points out, R & D capital expen-
ditures, reinvestment would have been a nice place to put it. That's an awful
lot of money compared to what they did spend, which was a tenth of the re-
serve and a seventh of what they have actually spent.
Vioxx is another recent highly publicized example, Mark Lanier's case
with $253 million dollars in one suit. I think this week there was a split ver-
dict, two verdicts, one in favor of the defendant, one in favor of the plaintiff;
just this past week - I think it was Wednesday - of $4.5 million dollars.5
Compare that, of course, to the $4.1 billion dollars that America had in its R
& D to spend compared to what it now has reserved at $50 billion dollars,55
so it is running at about a 10 to 1 ratio what they are reserving for these costs
versus R & D.
That says it all in my opinion in terms of innovation opportunities for
these important companies. There is a purpose for product liability. I am not
coming at this from just one side, but we would all agree going back. There
is a place for and well thought out law to make a difference. The problem is
the damages exposure has now gone so far off the deep end and that not only
is there an incentive to stop making products altogether, but the incentives
have become so skewed that the exit altogether from the market option be-
comes more attractive.
Of course, as we saw with the vaccine, for example, price increases are
the short-term solution. There are some assumptions that go into that, and
that is pursuing improvements will increase the liability prospects and reduce
exposure, and that exposure correlates with harm caused. In practice, it does-
n't quite work out that way.
Let's take a couple of examples. In my experience, the self-evaluation
problem is one of the least understood by legislators in this mix, and I will
give you an example from a different scenario where the top researcher for a
client of ours - this is all public information - wrote on a budget in 1968
some comments about where the budget was going to go for research that
next year. It was well intended. He wanted to have more funds for a particu-
lar arm of research being done. Of course, that document became producible
54 See generally Diedtra Henderson, Jury Awards Another $9 million in Vioxx Lawsuit,
BOSTON GLOBE, Apr. 12, 2006, at DI (Describing how John McDarby was awarded $4.5
million in damages, but Thomas Cona was only reimbursed for the costs of his Vioxx pre-
scription; the jury found Merck failed to warn about the cardiovascular risks associated with
Vioxx).
55 See generally Browning-Ferris Indus. V. Kelco Disposal, Inc., 492 U.S. 257, 282 (1989)
(O'Connor, J., concurring in part and dissenting in part) (Observing that "as recently as a
decade ago, the largest award of punitive damages affirmed by an appellate court in a products
liability case was $ 250,000" but, [s]ince then, awards more than 30 times as high have been
sustained on appeal").
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in 1986, twenty years later, when litigation involving children's injuries
arose, and this gentleman, who is now well into his retirement, well into his
70s, became almost attached to the hip with me and other lawyers around the
country. Why? Because he was getting depositions until he was 85 on that
one comment on the budget in 1966. If there were a self-critical evaluation
privilege - by that I mean within the mounds of fair commentary on where a
company ought to be criticizing its own resource allocation performance,
pros and cons of products for innovative opportunities, basically applying the
scientific method of critical analysis without fear of litigation consequences,
I dare say that this man would have had a better retirement in Florida playing
golf than he had as it turned out.
There has been empirical research to show as recently as last year that
there is very little connection between the harm caused and product liability
costs that are incurred.56 Over half of the total costs go to the administration
of the process and to lawyers' fees.57 Compensation for pecuniary losses,
actual financial costs, not pain and suffering, not the intangible non-
economic component is just 22 percent of that total. 58
This slide is in a way mislabeled. I wouldn't call it just incentives to settle
meritorious cases but also incentives to settle meretricious cases, specious
cases as well, and why do I say that? Because the defense costs, for example,
for a company like Wyeth, one of the aid developers of pharmaceutical pro-
duction, makers of Advil and other over the counter products as well have
become so insurmountable that it affects share price.59 It affects R & D allo-
cations,60 and it just makes it at some point where they have got a bet the
company situation on their hands.6' That company has 60,000 lawsuits right
now facing it. They are in a bet the company situation; so therefore, they are
fighting these things on several fronts and with a very impressive proactive
strategy. And they are on the cutting edge doing things that other companies
56 See generally Facts About Tort Liability and its Impact on Consumers, AMERICAN TORT
REFORM Ass'N, 2005, available at http://www.atra.org/wrap/files.cgi/7963-howtortre-
form.html (describing the extreme costs of the US tort system as it amounts to the equivalent
of $845 for a family of four).
57 See generally id. (describing how the US tort system is inefficient as it returns less than
$.50 on the dollar and less than $.22 for actual economic loss to the claimants).
58 id.
59 See generally Ted Frank, American Enterprise Institutes Panel Discussion, the $253
Million Vioxx Verdict: What does it mean? (Sept 9, 2005) (discussing how the drop in
Merck's share price after the verdict amounted to a reduction of billions of dollars from the
economy).
60 See generally Mark Trumbull, Putting Limits on Liability, CHRISTIAN SCI. MONITOR,
June 11, 1992, at 8 (explaining how certain manufacturing companies are forced to spend
seven times more on product liability costs than on research and development of new prod-
ucts).
61 Id.
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I think will learn from. But there is always that risk of a run away jury, and,
folks, that can include the specter of punitive damages.
In a previous life, I was a reporter for the Associated Press, so my friends
tell me I am zero for two on careers of public esteem. But there is no ques-
tion that you see the PR impact play out in litigation as well and have conse-
quences. The Dow Coming bankruptcy is one good example where there was
tremendous publicity and quite a bit of sympathetic coverage of women who
had some significant injuries. 62 The question is: Was there a causal connec-
tion? Quite a few court-appointed experts and scientists have said that it
looks fairly clear that it wasn't the case; that there was a connection. 63 I had
not been in those cases and can't offer any more insights on that.
Wyeth acquired the company of American Home Products, AHP, which
owns A. H. Robbins, and for those of us who remember another mass tort
debacle for companies is the Dalcon Shield, and, of course, there was a tre-
mendous impact on share price there.64
The contrary incentive is, of course, to reduce liability. I would submit
that companies don't need to have this much incentive from the system.
There is overkill, and that good scientists with R & D budgets that will allow
them to do good work without the fear of having every document they write
become Exhibit 1 in litigation, that those are the ways to approach this, and
not in the ways that we have gone.
Clearly, the FDA previously on the sidelines has now become much more
concerned about the unclear and complicated warnings on pharmaceuticals.65
For those of us, and those of you, who have watched the television adver-
tisements on pharmaceutical products, it never ceases to amaze me how far
that has come. Just ten years ago it was unthinkable to have television adver-
tising, but they still try to work in the adverse affects because the FDA is
making clear there must be balance. 66 There are some hell holes in this coun-
62 See generally Jeannie Kever & Mike Tolson, Silicon's Long Legal Battle Yields Cash,
Few Answers, HOUSTON CHRONICLE, June 13, 2004, at 37 (describing extent of publicity).
63 See, e.g., Glenn Swogger, Breast Implant Controversy Reflects Love-Hate Relationship
with Science, AUGUSTA CHRONICLE, Feb. 17, 1997, at A5 (explaining how major research
studies have shown little or no relationship between silicone and autoimmune disease).
64 See generally Rhonda Cook, Georgia Bill Seeks to Cap Medical Malpractice Damage
Awards, ATL. J. & CONST., Feb 12, 2003 (discussing the Dalcon Shield birth control litigation
of the 1970s).
65 See Judyth Pendell, The Adverse Side Effects of Pharmaceutical Litigation, AEI -
BROOKINGS JOINT CENTER FOR REGULATORY STUDIES, Sept 1989, at 5 available at
http://www.aei-brookings.org/admin/authorpdfs/page.php?id=293 (noting that according to
FDA Commissioner Dr. Mark McClellan, "[slo long as the product developers we work with
are facing an environment in which any adverse outcome can result in a major lawsuit, we
may get labels written for lawyers, not doctors and patients").
66 See generally id. at 5 (explaining how warnings should convey risk and are tools for
allowing doctors to help patients and that they should not be risk management tools to avoid
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try; ATRA, the American Tort Reform Association, has identified a number
of them, and I can cite several of them from personal experience. 67 More on
that in a minute. Windfall damages, of course, are well publicized.
Self-critical evaluation we talked about, and then there are personal re-
sponsibility issues that if we step back and ask ourselves, where is that going
in this country and where is causation?
You have heard of the Bridges of Madison County; I call this the judges
of Madison County. About five hours south of where I practice, six hours
south in Madison County there is more than four times the average of Illi-
nois. A $10 million-dollar price victory versus Phillip Morris was over-
turned, 68 but the plaintiff lawyers in that case I am sure will fight another
day. This is a very small county. Yet, it has 298 class actions over the course
of just several years. 69 Largely because of places like Madison County, you
have the Class Action Fairness Act that was enacted last year.70 It is a good
start. The data on this slide shows that.
If you would like these slides as well, I would be happy to e-mail them to
you, so please feel free to give me your e-mail. I am running short on time. I
got the sign, but a couple of thoughts here on punitive damages.
Speaking of progress made, a State Farm case and the other cases related
to it have brought some much needed due process constraints on some of
these run away verdicts.71 The punch line here is if the ratio of punitive dam-
ages to compensatory begins to eek above 5, 7, 10, thereabouts, then it is
going to create greater problems for plaintiffs to sustain in the category of
pigs get fat but hogs get slaughtered. And that's an important rule of thumb
that I have seen play out since the State Farm case came down.
There are some state law restrictions, but many states, including Illinois,
have had constitutional challenges to those statutes.72 A great success story in
lawsuits).
67 See, e.g., Judicial Hellholes 2005, AMERICAN TORT REFORM AssoC., 2005, available at
http://www.atra.org/reports/hellholes/report.pdf (describing West Virginia, South Florida and
Madison County, I1. as examples of hell holes).
68 See generally id. at 20 (describing how a lawsuit was brought against not just Phillip
Morris, but also the local convenience store operators who sell cigarettes).
69 See id. at 21 (describing how the week prior to the Class Action Fairness Act being
passed, lawyers filed at least 34 class actions).
70 See generally Barbara L. Jones, Study Reports Act Serves its Purpose: Moving Class
Actions, DAILY RECORD (K.C., Mo.), Oct. 25, 2006 (reporting that purpose of Class Action
Fairness Act is to shift litigation from state to federal court).
71 See, e.g., Avery v. State Farm Mut. Auto. Ins. Co., 26 I11. 2d 100 (Ill. 2005) (explaining
that a state trial judge should not have granted nationwide class action treatment).
72 See generally, Lisa M. Bass, The Class Action Fairness Act: What's Fair About It,
AMERICAN U. Bus. L. BRIEF, Fall 2005, at 23-25 (describing how CAFA may undermine the
Supreme Court's decision in Erie v. Tompkins because it allows Congress to declare specific
procedural rules of common law).
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this country is Home Depot.73 Co-founder Bernie Marcus said he didn't think
he could have performed Home Depot today if he were facing the same li-
ability scenario that exists.74
And a no good deed goes unpunished. I have talked a little bit about self-
critical analysis, and I recently litigated this in two or three states, and you
find even where there are states that have precedent that support the right of
companies to evaluate shortcomings in their programs, not just a right but a
duty now under Sarbanes-Oxley, 75 that Sarbanes-Oxley and self-critical
analysis case law are going to have a train wreck pretty soon.76 Companies
have to engage in this process. If they don't, they will face significant expo-
sures, and yet, a client of mine that hired one major accounting firm to ana-
lyze problems in his process found that document was immediately sought in
litigation and is now going to be Exhibit 1 in our trial next month.
It astonishes people from outside this country that seat belt laws still exist;
that the failure of people to use seat belts despite statutes remains inadmissi-
ble.77 Likewise, intoxication evidence often is inadmissible.78
Our time is up. There are a few other slides here that talk about other is-
sues. I would like to fast forward, though, to two areas as I wrap up. These
are both areas that I think we can focus. I don't think it is realistic to expect
massive sweeping reform at any one time. It was tried in Illinois in 1996
when the planets were aligned; you had a Republican assembly, a Republican
Senate, a Republican governor, and within six months, you had this sweeping
tort reform bill, caps on damages, you name it.
79
The case that I just cited, the best was a 4-3 decision overturning that
statute on constitutional grounds. Therefore, you have to look at smaller
steps. One of those I think is to bring Daubert, the federal standard for gate-
73 See, e.g., Brian Grow, Home Depot: Thinking Outside of the Box, Bus. WK., October 25,
2004, at http://www.businessweek.com/magazine/content/04_43/b3905090-mzO7.htm (Ex-
plaining how Home Depot was ranked #22 on Business Week's best-performing large public
companies in 2004).
74 Bernie Marcus, Opinion, America's Litigation Crisis, CENTER FOR INDIVIDUAL
FREEDOM, Sept. 15, 2004, at http://www.cfif.org/htdocs/freedomnline/current/guestcommen-
tary/americanlitigationscrisis.htm.
75 Kathleen F. Brickey, From Enron to WorldCom and Beyond: Life and Crime After Sar-
banes-Oxley, 81 WASH. U. L.Q. 357 (2003); Sarbanes-Oxley Act of 2002, Pub. L. No. 107-
204, 116 Stat. 745 (codified in scattered sections of the U.S.C.A.).
76 See Brickey, supra note 53.
77 Tori. R. A. Kricken, The Viability of "The Seatbelt Defense" in Wyoming - Implications
of and Issues Surrounding Wyoming Statute § 31-5-1402(F), 5 WYO. L. REV. 133, 167-168
(2005).
78 See, e.g., Englehart v. Jeep Corp., 122 Ariz. 256 (Ariz. Sup. Ct. 1979) (noting that hold-
ing evidence of motorist's intoxication was admissible only to show that an accident was
caused by reckless driving).
79 Limitations on Recovery of Non-Economic Damages, 735 ILL. COMP. STAT. 5/2-1115.1
(1995).
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keeper roles for judges in federal court, to the state courts. Very few states
have adopted Daubert.8° Second is to make cost shifting really meaningful. In
this country, in most states, the cost of litigation is never shifted in traditional
product liability cases. When I sat on an ABA Task Force on civil justice
reform, we actually -
DR. KING: You better wind up pretty soon.
MR. ROBINSON: I am going to overrule the timekeeper, Henry. We
have lots of time.
DR. KING: You are not going to overrule anyone.
MR. ROBINSON: It is only 4:17. We started a bit early, and I think this is
very important what Michael is telling us, so let's let him finish, please.
MR. WAGNER: Well, I will make it quick. The bottom line is that we
proposed a cost-shifting mechanism that would put expert witness fees into
that process and make it so that when an offer was made and rejected by
plaintiffs, then plaintiffs who did not get a good result, a better result than the
offer, will be required to pay the expert costs. We actually persuaded plain-
tiffs' lawyers to go along with this in committee, but when the ABA House of
Delegates dominated by plaintiffs' lawyers got their hands on it, it was basi-
cally dead on arrival. I would like to see that revisited some time.
To wrap up, I think to borrow a term from the warranty language, product
liability laws, Michael, are not fit for their intended purpose here in the states
and comprehensive reform is required. If there is reform, hopefully, we won't
have these things looking at us on our tombstone.
So thank you.
DISCUSSION FOLLOWING THE PRESENTATIONS OF BRUCE A.
THOMAS, QC AND MICHAEL J. WAGNER
MR. ROBINSON: Thank you very much. That was excellent. I am going
to set another precedent, partial precedent and not let Henry ask the first
question only because I already put this question out to Michael earlier -
sorry - to Bruce earlier. I would be very interested to hear, Bruce, your
views, if any, on the fact that we now have contingent fees permitted in cer-
tain circumstances in class actions and what certain circumstances might do
to product liability litigation in Ontario and Canada in the near future?
MR. THOMAS: Let me answer it in this way. First, the largest punitive
damage award in Canada is $1 million dollars. Secondly, in terms of personal
injuries, our Supreme Court of Canada in 1978 capped the general damages,
that's the pain and suffering damages at $100,000, and with inflation, that
80 See Stephen Mahle, The Impact of Daubert v. Merrell Dow Pharmaceuticals, Inc., on
Expert Testimony with Applications to, THE FLORIDA BAR JOURNAL, March, 1999, at 36 (dis-
cussing how nineteen states had adopted Daubert).
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